New studies fail to find cardiovascular risk with testosterone therapy

Two recent studies failed to find a connection between testosterone therapy in men and heart problems, contradicting research that prompted the US Food and Drug Administration to investigate its safety. The new studies include a meta-analysis of data from 29 studies involving more than 120,000 men and an observational study from a Wisconsin health system.



from Today's Healthcare News -- ScienceDaily http://ift.tt/1CQRYit

Personalized health coaching helps reverse progression to diabetes

People with prediabetes who took part in a comprehensive health program to improve nutrition, exercise, stress and sleep were able to revert to normal blood glucose metabolism, reducing their risk for developing diabetes--a known risk factor for cardiovascular disease -- according to a new study.



from Today's Healthcare News -- ScienceDaily http://ift.tt/1CQRVU1

High need for treatment of transgender youth

A new study has confirmed that transgender youth often have mental health problems and that their depression and anxiety improve greatly with recognition and treatment of gender dysphoria.



from Today's Healthcare News -- ScienceDaily http://ift.tt/1MhvVkS

Liraglutide may help overweight and obese adults lose weight safely and effectively

Obesity guidelines recommend an initial weight loss goal of 5 to 10 percent of start weight to improve health. A recent study found that patients who received liraglutide 3.0 mg, combined with fewer calories and more physical activity, were more than twice as likely to achieve at least that level of weight loss, compared to patients on placebo who made similar lifestyle changes.



from Today's Healthcare News -- ScienceDaily http://ift.tt/1EETV0o

Covalon announces introduction of new MediClear product line to reduce surgical site infections

Covalon Technologies Ltd, an advanced medical technologies company, today announced the introduction of its new MediClear product line designed to significantly improve patient compliance with efforts to reduce surgical site infections (SSI).



from The Medical News http://ift.tt/1EskXK2

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

Astellas today announced that the U.S. Food and Drug Administration has approved its New Drug Application (NDA) for the use of CRESEMBA (isavuconazonium sulfate), the prodrug for isavuconazole, for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis).



from The Medical News http://ift.tt/1DY9KeR

24 Hacks That Will Make You Love Morning Workouts